Skip to main content

Table 1 Characteristics of the studied population (n = 165)

From: Determinants of vascular function in patients with type 2 diabetes

Demographics
 Age, years 66 (40, 80)
 Female gender, n (%) 116 (70)
 Time since diagnosis of diabetes, years 10 (1, 33)
 Smoking, n (%) 28 (17)
 Hypertension, n (%) 131 (79)
 Antihypertensive medications, n (%) 109 (66)
  ACE-I/ARBs 84 (51)
  Calcium channel blockers 58 (35)
  Diuretics 24 (15)
  Beta blockers 13 (8)
 Hypercholesterolemia, n (%) 150 (91)
 Statins, n (%) 48 (29)
 Oral antidiabetic medication, n (%) 129 (78)
  Sulfonylureas 98 (59)
  Metformin 89 (54)
 Insulin treatment, n (%) 36 (22)
 Body mass index, kg/m2 30.1 ± 5.5
Laboratory investigations
 Fasting glucose, mmoL/L 9.4 ± 2.7
 HbA1c, % 8.3 ± 1.2
 Total cholesterol, mmoL/L 5.6 ± 1.0
 HDL-c, mmoL/L 1.3 ± 0.3
 Triglycerides, mmoL/L 1.7 ± 0.8
 LDL-c, mmoL/L 3.4 ± 0.9
 Creatinine, μmoL/L 78.7 ± 17.7
 Glomerular filtration rate, ml/min/1.73 m2 78.1 ± 16.3
 High sensitivity C-reactive protein, mg/l 1.84 (0.31, 9.71)
 Albumin to Creatinine ratio, mg/mmol 1.20 (0.18, 34.50)
 Microalbuminuria, n (%) 31 (19)
Vascular measurements
 Heart rate, beats/min 72 ± 11
 Systolic blood pressure, mmHg 146 ± 15
 Diastolic blood pressure, mmHg 78 ± 7
 Flow-mediated dilation, % 1.98 ± 1.66
 Nitrate-mediated dilation, % 10.09 ± 3.84
 Carotid-femoral pulse wave velocity, m/sec 10.2 ± 2.2
  1. Continuous data are presented as mean ± SD. For not normally distributed variables (age, time since diagnosis of diabetes, high sensitivity C-reactive protein and urine albumin to creatinine ratio) data are presented as median (range). ACE-I, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; HbA1c, glycated hemoglobin; HDL-c, high density lipoprotein cholesterol; LDL-c, low density lipoprotein cholesterol.